Abstract
The case of myelopathy after radiotherapy and chemotherapy, reported by Seddon et al. [ 1 Seddon B.M. Cassoni A.M. Galloway M.J. et al. Fatal radiation myelopathy after high-dose busulfan and melphalan chemotherapy and radiotherapy for Ewing's sarcoma: a review of the literature and implications for practice. Clin Oncol. 2005; 17: 385-390 Abstract Full Text Full Text PDF Scopus (36) Google Scholar ], is of interest. The authors present a case of fatal cervical myelopathy in a 17-year-old boy who received neck and upper thoracic radiotherapy after high-dose alkylating-agent chemotherapy with busulphan and melphalan. Although the risk of radiation myelopathy following the delivery of 50 Gy mid-plane dose, conventionally fractionated to the neck by parallel-opposed, anterior and posterior, 6 MV X-ray portals is small, it is nonetheless present. The possibility of augmentation of that risk (i.e. reduced tissue tolerance to radiation) by alkylating-agent chemotherapy is intriguing, as this phenomenon is really only widely appreciated for intercalating drugs such as anthracyclines and actinomycin D, and the synergised central nervous system toxicity of methotrexate with radiotherapy [ 2 Phillips T.L. Radiation drug interactions in the treatment of cancer. Wiley, New York1980 Google Scholar ].
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
